GlassScriptPhysician profile
Joel Andrew Ohrt
NPI 1003341983
$274.97
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.00 · 2020: $22.58 · 2021: $147 · 2022: $90.50.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.42 | 2020-2021 | |
| Glaxosmithkline, LLC. | $41.77 | 2021-2022 | |
| Genzyme Corporation | $36.45 | 2022 | |
| Novo Nordisk INC | $35.50 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.45 | 2021 | |
| Grifols USA, LLC | $20.70 | 2021 | |
| Esperion Therapeutics, INC. | $19.41 | 2021 | |
| United Therapeutics Corporation | $18.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.46 | 2022 | |
| Electromed, INC. | $16.81 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Ohrt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.